Trastuzumab Deruxtecan (T-DXd): Tailoring Treatment and Companion Diagnostics (CDx) by Liquid Biopsy

NCT05919212 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DIAGNOSTIC_TEST: HER2-D is the use of a non-invasive liquid biopsy method to non-invasively and objectively assess HER2 status at recruitment

Sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS